Sangamo Therapeutics (SGMO) and Pfizer (PFE) Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
| Pfizer Inc. (NYSE: PFE) | Delayed: 28.28 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.28 | 52 Week High | $37.39 | |||
| Open | $28.28 | 52 Week Low | $28.25 | |||
| Day High | $28.28 | P/E | 17.14 | |||
| Day Low | $28.28 | EPS | $1.65 | |||
| Volume | 63,127 | |||||
| Sangamo Biosciences, Inc. (NASDAQ: SGMO) | Delayed: 0.18 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.18 | 52 Week High | $9.91 | |||
| Open | $0.18 | 52 Week Low | $3.10 | |||
| Day High | $0.18 | P/E | N/A | |||
| Day Low | $0.18 | EPS | $-0.48 | |||
| Volume | 9 | |||||
